Edge Therapeutics Announces Conference Call on March 2, 2017 to Discuss Fourth Quarter and Full Year 2016 Financial Results
February 23 2017 - 7:00AM
Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage
biotechnology company developing novel hospital-based therapies in
the management of acute, life-threatening conditions, today
announced that it will host a conference call on Thursday, March 2,
2017 at 8:30 a.m. ET to discuss its fourth quarter and full year
2016 financial results.
The conference call will be available via phone and
webcast. To access the call, please dial (877) 388-5691, or (562)
350-0788 for international callers, and reference participant code
65067360 approximately 15 minutes prior to the call. A replay of
the call may be accessed through March 16, 2017 on the investor
section of Edge’s website or by dialing (855) 859-2056, or (404)
537-3406 for international callers, and referencing participant
code 65067360. A live webcast of the conference call will be
available on the investor relations section of Edge’s website at
www.edgetherapeutics.com.
About Edge Therapeutics, Inc.Edge
Therapeutics, Inc. is a clinical-stage biotechnology company that
discovers, develops and seeks to commercialize novel,
hospital-based therapies capable of transforming treatment
paradigms for the management of acute, life-threatening
neurological and other conditions. EG-1962, Edge’s lead product
candidate, has the potential to fundamentally improve patient
outcomes and transform the management of aneurysmal subarachnoid
hemorrhage, which is bleeding around the brain due to a ruptured
brain aneurysm. Edge is evaluating EG-1962 in two clinical studies:
a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via external
ventricular drain, and a study of direct intracisternal
administration of EG-1962. For additional information about Edge,
please visit www.edgetherapeutics.com.
Forward-Looking StatementsThis
press release and any statements of representatives of Edge
Therapeutics, Inc. related thereto that are not historical in
nature contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements may include, without limitation, statements with respect
to Edge’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," “seeks,” "intends," "plans,"
"potential" or similar expressions, including statements with
respect to Edge’s future clinical plans, Edge’s ability to advance
its portfolio of therapies towards commercialization and the
potential effects of its products. These statements are based upon
the current beliefs and expectations of Edge’s management and are
subject to significant risks and uncertainties. Actual results may
differ significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks
and uncertainties that are subject to change based on various risk
factors (many of which are beyond Edge's control) as described
under the heading "Risk Factors" in Edge’s filings with the United
States Securities and Exchange Commission.
Investor Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: ir@edgetherapeutics.com
Media Contact:
Laura Bagby
6 Degrees
Tel: 312-448-8098
Email: lbagby@6degreespr.com
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jul 2023 to Jul 2024